Login
Companies $CAI
$21.50 +$0.50 (2.38%) After hours
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc.

carislifesciences.com

What Do They Do?

Sells molecular profiling tests using tissue and blood to help physicians select cancer treatments, and provides biopharma companies with molecular data and research services for drug development.

How Do They Make Money?

Molecular profiling brings payments from patients, hospitals, and commercial or government insurers for tests, typically collected within 90 to 120 days of billing after results reach ordering physicians. Biopharma customers pay for research services over the service period, including through milestone payments and ongoing support.

revenue
SegmentShareRevenue
Cost of services - Molecular profiling services
Sold outright

94%
Cost of services - Pharma research and development services
Recurring
5.6%

Who Are Their Customers?

Treating physicians order clinical profiling, while biopharma companies and researchers use Caris's data and research services. International hospital systems are served through distributors or direct contracts.

Do Revenues Turn Into Profits?

Not on paper. It lost $68.1M in FY2025, but brought in more cash than it spent: $66.9M of free cash flow.

Operating income, FY2025
6% of revenue
▲ Turned profitable vs FY2024 (−$257.1M, −62%)
Net income, FY2025
−8% of revenue
▲ +76% (Loss) vs FY2024 (−$281.9M, −68%)
Free cash flow, FY2025
8% of revenue
▲ Turned profitable vs FY2024 (−$253.6M, −62%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +27%
vs $216.8M in Q3 FY2025
Net income
▼ −37%
vs $24.3M in Q3 FY2025
Cost of services - Molecular profiling services share of revenue vs 95.7% in Q3 FY2025
  • Aug 5, 2026 Raised revenue guidance Now expects full-year 2026 revenue of $1.03 billion to $1.04 billion, representing growth of 27% to 28%.
Revenue over time
Cost of services - Molecular profiling services Cost of services - Pharma research and development services
$1B$500M$0

Who Do They Compete With?

Competes with Foundation Medicine, Tempus, Memorial Sloan Kettering Cancer Center, New York Presbyterian—Weil Cornell, Grail, Freenome, Guardant Health, Exact Sciences, Delfi Diagnostics, Natera, SAGA Diagnostics, Personalis, BillionToOne, Quest Diagnostics, Adaptive Biotechnologies, Illumina, NeoGenomics, Myriad Genetics, Laboratory Corporation of America, and BostonGene

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support